Guardant Health, Inc. (NASDAQ:GH) Shares Bought by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. boosted its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 1,902.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 454,500 shares of the company's stock after purchasing an additional 431,800 shares during the quarter. Polar Asset Management Partners Inc. owned about 0.37% of Guardant Health worth $13,885,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of GH. Vanguard Group Inc. grew its holdings in shares of Guardant Health by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock worth $368,205,000 after purchasing an additional 350,606 shares in the last quarter. Deep Track Capital LP grew its stake in Guardant Health by 7.0% in the 4th quarter. Deep Track Capital LP now owns 6,419,566 shares of the company's stock worth $196,118,000 after buying an additional 419,006 shares in the last quarter. Two Sigma Advisers LP increased its holdings in shares of Guardant Health by 96.7% in the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company's stock worth $70,742,000 after buying an additional 1,138,300 shares during the last quarter. Two Sigma Investments LP raised its position in shares of Guardant Health by 38.5% during the 4th quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company's stock valued at $57,761,000 after buying an additional 525,368 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Guardant Health by 19.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after acquiring an additional 238,037 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Amirali Talasaz sold 106,784 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the sale, the chief executive officer now owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. The trade was a 4.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 107,132 shares of company stock worth $5,248,393 over the last quarter. Company insiders own 6.10% of the company's stock.

Guardant Health Price Performance

Shares of GH traded up $2.20 during midday trading on Friday, hitting $40.75. The stock had a trading volume of 992,922 shares, compared to its average volume of 2,128,142. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $52.92. The firm has a market cap of $5.05 billion, a PE ratio of -11.45 and a beta of 1.49. The stock's 50 day moving average is $42.79 and its 200 day moving average is $40.35.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.08. The company had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm's revenue was up 20.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.46) EPS. As a group, equities research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GH has been the topic of a number of research reports. Guggenheim reissued a "buy" rating and set a $56.00 price objective on shares of Guardant Health in a report on Monday, February 24th. UBS Group increased their target price on Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a report on Thursday, May 1st. Scotiabank restated an "outperform" rating on shares of Guardant Health in a research report on Monday, May 5th. Mizuho initiated coverage on Guardant Health in a research report on Thursday, April 10th. They issued an "outperform" rating and a $55.00 price objective for the company. Finally, Morgan Stanley raised their target price on shares of Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th. Twenty-one analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $52.32.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.